Targeting anillin inhibits tumorigenesis and tumor growth in hepatocellular carcinoma via impairing cytokinesis fidelity.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
05 2022
Historique:
received: 17 10 2021
accepted: 08 03 2022
revised: 21 02 2022
pubmed: 29 4 2022
medline: 31 5 2022
entrez: 28 4 2022
Statut: ppublish

Résumé

Targeting cytokinesis can suppress tumor growth by blocking cell division and promoting apoptosis. We aimed to characterize key cytokinesis regulator in hepatocellular carcinoma (HCC) progression, providing insights into identifying promising HCC therapeutic targets. The unbiased bioinformatic screening identified Anillin actin binding protein (ANLN) as a critical cytokinesis regulator involved in HCC development. Functional assay demonstrated that knockdown of ANLN inhibited HCC growth by inducing cytokinesis failure and DNA damage, leading to multinucleation and mitotic catastrophe. Mechanistically, ANLN acts as a scaffold to strengthen interaction between RACGAP1 and PLK1. ANLN promotes PLK1-mediated RACGAP1 phosphorylation and RhoA activation to ensure cytokinesis fidelity. To explore the function of ANLN in HCC tumorigenesis, we hydrodynamically transfected c-Myc and NRAS plasmids into Anln

Identifiants

pubmed: 35477750
doi: 10.1038/s41388-022-02274-1
pii: 10.1038/s41388-022-02274-1
doi:

Substances chimiques

Contractile Proteins 0
Microfilament Proteins 0
anillin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3118-3130

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020;72:215–29.
doi: 10.1016/j.jhep.2019.08.017
Li Z, Zhu JY. Hepatocellular carcinoma: current situation and challenge. Hepatobiliary Pancreat Dis Int. 2019;18:303–4.
doi: 10.1016/j.hbpd.2019.05.013
Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M. Predictors of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci. 2019;24:86.
doi: 10.4103/jrms.JRMS_1017_18
Chaikovsky AC, Li C, Jeng EE, Loebell S, Lee MC, Murray CW, et al. The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D. Nature. 2021;592:794–8.
doi: 10.1038/s41586-021-03474-7
Simoneschi D, Rona G, Zhou N, Jeong YT, Jiang S, Milletti G, et al. CRL4(AMBRA1) is a master regulator of D-type cyclins. Nature. 2021;592:789–93.
doi: 10.1038/s41586-021-03445-y
Maiani E, Milletti G, Nazio F, Holdgaard SG, Bartkova J, Rizza S, et al. AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature. 2021;592:799–803.
doi: 10.1038/s41586-021-03422-5
Lens S, Medema RH. Cytokinesis defects and cancer. Nat Rev Cancer. 2019;19:32–45.
doi: 10.1038/s41568-018-0084-6
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
doi: 10.1016/j.cell.2011.02.013
Zhang S, Nguyen LH, Zhou K, Tu HC, Sehgal A, Nassour I, et al. Knockdown of anillin actin binding protein blocks cytokinesis in hepatocytes and reduces liver tumor development in mice without affecting regeneration. Gastroenterology. 2018;154:1421–34.
doi: 10.1053/j.gastro.2017.12.013
Xu M, Wang F, Li G, Wang X, Fang X, Jin H, et al. MED12 exerts an emerging role in actin-mediated cytokinesis via LIMK2/cofilin pathway in NSCLC. Mol Cancer. 2019;18:93.
doi: 10.1186/s12943-019-1020-4
Yang XM, Cao XY, He P, Li J, Feng MX, Zhang YL, et al. Overexpression of Rac GTPase activating protein 1 contributes to proliferation of cancer cells by reducing hippo signaling to promote cytokinesis. Gastroenterology. 2018;155:1233–49.
doi: 10.1053/j.gastro.2018.07.010
Pallavicini G, Sgro F, Garello F, Falcone M, Bitonto V, Berto GE, et al. Inactivation of citron kinase inhibits medulloblastoma progression by inducing apoptosis and cell senescence. Cancer Res. 2018;78:4599–612.
doi: 10.1158/0008-5472.CAN-17-4060
Chen J, Jia X, Li Z, Song W, Jin C, Zhou M, et al. Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma. Biochem Pharmacol. 2021;188:114494.
doi: 10.1016/j.bcp.2021.114494
Lian YF, Huang YL, Wang JL, Deng MH, Xia TL, Zeng MS, et al. Anillin is required for tumor growth and regulated by miR-15a/miR-16-1 in HBV-related hepatocellular carcinoma. Aging. 2018;10:1884–901.
doi: 10.18632/aging.101510
Suzuki C, Daigo Y, Ishikawa N, Kato T, Hayama S, Ito T, et al. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res. 2005;65:11314–25.
doi: 10.1158/0008-5472.CAN-05-1507
Wang A, Dai H, Gong Y, Zhang C, Shu J, Luo Y, et al. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis. J Exp Clin Cancer Res. 2019;38:347.
doi: 10.1186/s13046-019-1340-7
Zhou W, Wang Z, Shen N, Pi W, Jiang W, Huang J, et al. Knockdown of ANLN by lentivirus inhibits cell growth and migration in human breast cancer. Mol Cell Biochem. 2015;398:11–9.
doi: 10.1007/s11010-014-2200-6
Budnar S, Husain KB, Gomez GA, Naghibosadat M, Varma A, Verma S, et al. Anillin promotes cell contractility by cyclic resetting of RhoA residence kinetics. Dev Cell. 2019;49:894–906.
doi: 10.1016/j.devcel.2019.04.031
Gentric G, Desdouets C. Polyploidization in liver tissue. Am J Pathol. 2014;184:322–31.
doi: 10.1016/j.ajpath.2013.06.035
Duncan AW, Taylor MH, Hickey RD, Hanlon NA, Lenzi ML, Olson SB, et al. The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature. 2010;467:707–10.
doi: 10.1038/nature09414
Zhang S, Zhou K, Luo X, Li L, Tu HC, Sehgal A, et al. The polyploid state plays a tumor-suppressive role in the liver. Dev Cell. 2018;44:447–59.
doi: 10.1016/j.devcel.2018.01.010
Wilkinson PD, Delgado ER, Alencastro F, Leek MP, Roy N, Weirich MP, et al. The polyploid state restricts hepatocyte proliferation and liver regeneration in mice. Hepatology. 2019;69:1242–58.
doi: 10.1002/hep.30286
Zhao WM, Fang G. MgcRacGAP controls the assembly of the contractile ring and the initiation of cytokinesis. Proc Natl Acad Sci USA. 2005;102:13158–63.
doi: 10.1073/pnas.0504145102
Burkard ME, Maciejowski J, Rodriguez-Bravo V, Repka M, Lowery DM, Clauser KR, et al. Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol. 2009;7:e1000111.
doi: 10.1371/journal.pbio.1000111
Wolfe BA, Takaki T, Petronczki M, Glotzer M. Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF complex to initiate cleavage furrow formation. PLoS Biol. 2009;7:e1000110.
doi: 10.1371/journal.pbio.1000110
Chen J, Xuan Z, Song W, Han W, Chen H, Du Y, et al. EAG1 enhances hepatocellular carcinoma proliferation by modulating SKP2 and metastasis through pseudopod formation. Oncogene. 2021;40:163–76.
doi: 10.1038/s41388-020-01522-6
Donne R, Saroul-Ainama M, Cordier P, Celton-Morizur S, Desdouets C. Polyploidy in liver development, homeostasis and disease. Nat Rev Gastroenterol Hepatol. 2020;17:391–405.
doi: 10.1038/s41575-020-0284-x
Qiao Y, Pei Y, Luo M, Rajasekaran M, Hui KM, Chen J. Cytokinesis regulators as potential diagnostic and therapeutic biomarkers for human hepatocellular carcinoma. Exp Biol Med. 2021;246:1343–54.
doi: 10.1177/15353702211008380
Zhang L, Maddox AS. Anillin. Curr Biol. 2010;20:R135–6.
doi: 10.1016/j.cub.2009.12.017
Piekny AJ, Maddox AS. The myriad roles of Anillin during cytokinesis. Semin Cell Dev Biol. 2010;21:881–91.
doi: 10.1016/j.semcdb.2010.08.002
Tuan NM, Lee CH. Role of anillin in tumour: from a prognostic biomarker to a novel target. Cancers. 2020;12:1600.
doi: 10.3390/cancers12061600
Lulli M, Coco LD, Mello T, Sukowati C, Madiai S, Gragnani L, et al. DNA damage response protein CHK2 regulates metabolism in liver cancer. Cancer Res. 2021;81:2861–73.
doi: 10.1158/0008-5472.CAN-20-3134
Ma H, Kang ZH, Foo TK, Shen ZY, Xia B. Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in hepatocellular carcinoma through cGAS-STING pathway. Hepatology. 2022. https://doi.org/10.1002/hep.32335 .
doi: 10.1002/hep.32335 pubmed: 35363898
Basant A, Glotzer M. Spatiotemporal regulation of RhoA during cytokinesis. Curr Biol. 2018;28:R570–80.
doi: 10.1016/j.cub.2018.03.045
Hodge RG, Ridley AJ. Regulating Rho GTPases and their regulators. Nat Rev Mol Cell Biol. 2016;17:496–510.
doi: 10.1038/nrm.2016.67
Su KC, Takaki T, Petronczki M. Targeting of the RhoGEF Ect2 to the equatorial membrane controls cleavage furrow formation during cytokinesis. Dev Cell. 2011;21:1104–15.
doi: 10.1016/j.devcel.2011.11.003
Matsumoto T, Wakefield L, Peters A, Peto M, Spellman P, Grompe M. Proliferative polyploid cells give rise to tumors via ploidy reduction. Nat Commun. 2021;12:646.
doi: 10.1038/s41467-021-20916-y
Lin H, Huang YS, Fustin JM, Doi M, Chen H, Lai HH, et al. Hyperpolyploidization of hepatocyte initiates preneoplastic lesion formation in the liver. Nat Commun. 2021;12:645.
doi: 10.1038/s41467-020-20572-8

Auteurs

Jian Chen (J)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Key Laboratory of the diagnosis and treatment of organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment For Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China.
Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China.

Zequn Li (Z)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Key Laboratory of the diagnosis and treatment of organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment For Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China.
Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China.

Xing Jia (X)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Key Laboratory of the diagnosis and treatment of organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment For Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China.
Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China.

Wenfeng Song (W)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Key Laboratory of the diagnosis and treatment of organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment For Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China.
Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China.

Hao Wu (H)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Key Laboratory of the diagnosis and treatment of organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment For Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China.
Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China.

Hai Zhu (H)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Key Laboratory of the diagnosis and treatment of organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment For Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China.
Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China.

Zefeng Xuan (Z)

Division of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Yehui Du (Y)

Division of Thyroid Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Xingxin Zhu (X)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Key Laboratory of the diagnosis and treatment of organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment For Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China.
Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China.

Guangyuan Song (G)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Key Laboratory of the diagnosis and treatment of organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment For Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China.
Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China.

Haijiang Dong (H)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Key Laboratory of the diagnosis and treatment of organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment For Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China.
Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China.

Suchen Bian (S)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Key Laboratory of the diagnosis and treatment of organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment For Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China.
Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China.

Shuo Wang (S)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Yongchao Zhao (Y)

NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.

Haiyang Xie (H)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Key Laboratory of the diagnosis and treatment of organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment For Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China.
Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China.

Shusen Zheng (S)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. shusenzheng@zju.edu.cn.
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China. shusenzheng@zju.edu.cn.
Key Laboratory of the diagnosis and treatment of organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment For Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China. shusenzheng@zju.edu.cn.
Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China. shusenzheng@zju.edu.cn.

Penghong Song (P)

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. songpenghong@zju.edu.cn.
NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China. songpenghong@zju.edu.cn.
Key Laboratory of the diagnosis and treatment of organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment For Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, China. songpenghong@zju.edu.cn.
Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China. songpenghong@zju.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH